Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
J Neural Transm (Vienna). 2015 Dec; 122(12):1709-14.JN

Abstract

Entacapone is frequently used together with levodopa/carbidopa (LC) and levodopa/benserazide (LB) in the treatment of Parkinson's disease (PD) patients with wearing-off symptoms. It is generally assumed that the effects of entacapone are independent of the type of decarboxylase inhibitor used, but there is very little published data available on the efficacy of entacapone administered with LB versus LC. We have performed a pooled analysis of three randomized, double-blind, 6-month, phase III studies to compare the treatment effects of entacapone (compared to placebo) in PD patients receiving LC or LB. A total of 551 PD patients experiencing wearing-off were included in the analysis. 300 patients were on LB and 251 on LC at baseline. At 6 months, entacapone (compared to placebo) improved mean daily OFF-time in patients on LB and LC by 0.76 (p = 0.016) and 0.95 (p = 0.011) hours, respectively. The corresponding improvements in ON-time were 0.97 (p = 0.002) and 0.83 h (p = 0.022), respectively. The treatment effects of entacapone both in LB and LC users were statistically significant (p < 0.05) also in UPDRS II and III scores, except in UPDRS II scores in patients receiving LC (p = 0.20). None of the treatment effects of entacapone were statistically significantly different between patients receiving LB or LC. Reported adverse events were comparable between LB and LC users. We conclude that entacapone provided comparable benefits in PD patients with wearing-off symptoms using either LB or LC.

Authors+Show Affiliations

Orion Pharma/R&D, P.O. Box 425, 20101, Turku, Finland. mikko.kuoppamaki@orionpharma.com.4Pharma AB, Stockholm, Sweden.Universitätsklinik für Neurologie, Leopold-Franzens-Universität, Innsbruck, Austria.

Pub Type(s)

Clinical Trial, Phase III
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26347184

Citation

Kuoppamäki, Mikko, et al. "Efficacy and Safety of Entacapone in Levodopa/carbidopa Versus Levodopa/benserazide Treated Parkinson's Disease Patients With Wearing-off." Journal of Neural Transmission (Vienna, Austria : 1996), vol. 122, no. 12, 2015, pp. 1709-14.
Kuoppamäki M, Leinonen M, Poewe W. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off. J Neural Transm (Vienna). 2015;122(12):1709-14.
Kuoppamäki, M., Leinonen, M., & Poewe, W. (2015). Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off. Journal of Neural Transmission (Vienna, Austria : 1996), 122(12), 1709-14. https://doi.org/10.1007/s00702-015-1449-6
Kuoppamäki M, Leinonen M, Poewe W. Efficacy and Safety of Entacapone in Levodopa/carbidopa Versus Levodopa/benserazide Treated Parkinson's Disease Patients With Wearing-off. J Neural Transm (Vienna). 2015;122(12):1709-14. PubMed PMID: 26347184.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off. AU - Kuoppamäki,Mikko, AU - Leinonen,Mika, AU - Poewe,Werner, Y1 - 2015/09/07/ PY - 2015/07/14/received PY - 2015/08/24/accepted PY - 2015/9/9/entrez PY - 2015/9/9/pubmed PY - 2016/9/10/medline KW - Benserazide KW - Carbidopa KW - Entacapone KW - Levodopa KW - Parkinson’s disease SP - 1709 EP - 14 JF - Journal of neural transmission (Vienna, Austria : 1996) JO - J Neural Transm (Vienna) VL - 122 IS - 12 N2 - Entacapone is frequently used together with levodopa/carbidopa (LC) and levodopa/benserazide (LB) in the treatment of Parkinson's disease (PD) patients with wearing-off symptoms. It is generally assumed that the effects of entacapone are independent of the type of decarboxylase inhibitor used, but there is very little published data available on the efficacy of entacapone administered with LB versus LC. We have performed a pooled analysis of three randomized, double-blind, 6-month, phase III studies to compare the treatment effects of entacapone (compared to placebo) in PD patients receiving LC or LB. A total of 551 PD patients experiencing wearing-off were included in the analysis. 300 patients were on LB and 251 on LC at baseline. At 6 months, entacapone (compared to placebo) improved mean daily OFF-time in patients on LB and LC by 0.76 (p = 0.016) and 0.95 (p = 0.011) hours, respectively. The corresponding improvements in ON-time were 0.97 (p = 0.002) and 0.83 h (p = 0.022), respectively. The treatment effects of entacapone both in LB and LC users were statistically significant (p < 0.05) also in UPDRS II and III scores, except in UPDRS II scores in patients receiving LC (p = 0.20). None of the treatment effects of entacapone were statistically significantly different between patients receiving LB or LC. Reported adverse events were comparable between LB and LC users. We conclude that entacapone provided comparable benefits in PD patients with wearing-off symptoms using either LB or LC. SN - 1435-1463 UR - https://www.unboundmedicine.com/medline/citation/26347184/Efficacy_and_safety_of_entacapone_in_levodopa/carbidopa_versus_levodopa/benserazide_treated_Parkinson's_disease_patients_with_wearing_off_ DB - PRIME DP - Unbound Medicine ER -